180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the
"Company"), a clinical-stage biotechnology company focused on the
development of novel drugs that fulfill unmet needs in inflammatory
diseases, fibrosis and pain, today announced that it has appointed
Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of
Directors (“Board”) effective June 15, 2021.
Russell Ray was formerly Managing Director and
Co-Head of Global Health Care at Credit Suisse First Boston
Corporation where he led a 50-person team with offices in
Baltimore, Chicago, London, New York and San Francisco focused on
providing corporate finance and M&A advisory services to
private and public companies in the biotechnology, health care
services and health care information technology sectors.
More recently, Mr. Ray was a Partner and Senior
Advisor to HLM Venture Partners, a health care focused venture
capital firm that invests in health care services, health care
information technology and medical technology companies. He
currently serves on the board of directors of Merrimack
Pharmaceuticals, Inc. (NASDAQ: MACK).
Russ is a former Captain in the United States Army
and recipient of the Bronze Star Medal, two Air Medals and two Army
Commendation Medals for Meritorious Service. He received his MBA in
Finance from the University of Pennsylvania’s Wharton School of
Business and graduated from the United States Military Academy at
West Point, New York.
Teresa DeLuca, MD, MBA comes to 180 Life Sciences
as both a public independent board director and former senior
executive Chief Medical Officer with significant P&L business
line ownership at global Fortune 50 companies. Dr. DeLuca has deep
expertise in operations, M&A, regulatory submissions,
divestures, spin outs and strategy.
Dr. DeLuca has 20+ years of corporate management
experience (GSK, Medco, Walgreens, Humana, Magellan), running large
divisions as well as being a physician with an active NY Medical
and DEA license. She has extensive knowledge in every vertical of
healthcare and has designed and launched new clinical services,
guided multiple business line expansions, as well as having
commercialized pharmaceutical in the highly competitive and
regulated healthcare industry (both domestic andinternational).
Her most recent role was at Columbia University as
Managing Director, NY Life Science Venture Fund which includes
leading the consortium of the 12 private/public institutions Her
responsibilities included providing due diligence support for
potential investments, partnerships, acquisitions,
commercialization, licensing, and IPOs.
Teresa completed her residency (MD) from Jefferson
Medical College of Thomas Jefferson University and received her MBA
from Drexel University. Additionally, a strong advocate for good
board governance, she earned the Carnegie Mellon Cybersecurity
certificate and passed the NACD’s “Directorship Certified”
examination (NACD.DC). Dr. DeLuca was also named “2020 Director to
Watch” in the “Directors & Board Annual Report.”
Dr. James Woody, 180 Life Sciences Chief Executive
Officer commented, “We are pleased to welcome both Teresa and Russ
to our Board. We took a considerable amount of time to not simply
just fill our open board seats, but to fill them with highly
qualified individuals who will immediately bring tangible value to
our team and capable of helping to create meaningful value for our
shareholders. I think both of their bios speak for themselves and I
look forward to working with them. Their addition will satisfy
Nasdaq’s continued listing standards for independent directors on
the 180 Life Sciences Board. In addition, we also look forward to
soon announcing the addition of two more equally qualified board
members to our team.”
About 180 Life Sciences Corp.
180 Life Sciences Corp. is a clinical-stage
biotechnology company focused on the development of novel drugs
that fulfill unmet needs in inflammatory diseases, fibrosis and
pain by leveraging the combined expertise of luminaries in
therapeutics from Oxford University, the Hebrew University and
Stanford University. 180 Life Sciences is leading the research into
solving one of the world’s biggest drivers of disease –
inflammation. The Company is driving groundbreaking studies into
clinical programs, which are seeking to develop novel drugs
addressing separate areas of inflammation for which there are no
effective therapies. The Company’s primary platform is a novel
program to treat fibrosis using anti-TNF (tumor necrosis
factor).
Forward-Looking Statements
This press release includes "forward-looking
statements", including information about management’s view of the
Company’s future expectations, plans and prospects, within the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 (the “Act”). Words such as “expect,” “estimate,”
“project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,”
“may,” “will,” “could,” “should,” “believes,” “predicts,”
“potential,” “continue” and similar expressions are intended to
identify such forward-looking statements. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from the expected
results and, consequently, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements and factors that may cause such
differences include, without limitation, statements relating to
expectations regarding the capitalization, resources, and funding
of the Company; expectations with respect to future performance,
growth and anticipated acquisitions; the continued listing of the
Company on The NASDAQ Stock Market; the ability of the Company to
execute its plans to develop and market new drug products and the
timing and costs of these development programs; estimates of the
size of the markets for its potential drug products; potential
litigation involving the Company or the validity or enforceability
of the intellectual property of the Company; global economic
conditions; geopolitical events and regulatory changes; the
expectations, development plans and anticipated timelines for the
Company's drug candidates, pipeline and programs, including
collaborations with third parties; access to additional financing,
and the potential lack of such financing; and the Company’s ability
to raise funding in the future and the terms of such funding. These
risk factors and others are included from time to time in documents
the Company files with the Securities and Exchange Commission,
including, but not limited to, its Form 10-Ks, Form 10-Qs and Form
8-Ks, as well as in the definitive proxy statement/prospectus that
the Company filed in connection with the recent merger. These
reports and filings are available at www.sec.gov. All subsequent
written and oral forward-looking statements concerning the Company
or other matters and attributable to the Company or any person
acting on its behalf are expressly qualified in their entirety by
the cautionary statements above. Readers are cautioned not to place
undue reliance upon any forward-looking statements, which speak
only as of the date made, including the forward-looking statements
included in this press release, which are made only as of the date
hereof. The Company cannot guarantee future results, levels of
activity, performance or achievements. Accordingly, you should not
place undue reliance on these forward-looking statements. The
Company does not undertake or accept any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statement to reflect any change in its expectations or any change
in events, conditions or circumstances on which any such statement
is based, except as otherwise provided by law.
Investors:
Jason AssadDirector of IR180 Life Sciences
Corp(678) 570-6791Jassad@180lifesciences.com
Media Relations:
David SchullDavid.Schull@russopartnersllc.com(212)
845-4271
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Apr 2024 to May 2024
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From May 2023 to May 2024